Condition: Hepatocellular Carcinoma (HCC) · Sponsor: Newish Technology (Beijing) Co., Ltd.
This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.
This description comes directly from the study's public registry record.
Zhen Huang, M.D. · 86-010-87787100 · huangzhen@cicams.ac.cn
Always discuss trial participation with your own doctor first.
| Beijing You'an Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| The Fifth Medical Center of Chinese PLA General Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Peking Union Medical College Hospital | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07324304